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Abstract Transcription of the human tissue-type plasminogen
activator (t-PA) gene is regulated by a multi-hormonal
responsive enhancer at 37 kb. Transient co-transfections of
Drosophila SL2 and human HT1080 fibrosarcoma cells with
t-PA reporter constructs showed that Sp1 and Sp3 activate the
t-PA promoter. Moreover Sp1 (but not Sp3) binding to the
promoter is involved in induction by retinoic acid (RA), a
response mediated through the enhancer. The role of Sp1 is
specific, since mutation of the CRE element in the promoter did
not affect response to RA. In contrast, the glucocorticoid
induction mediated by the enhancer is independent of these Sp1
and CRE elements.
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1. Introduction
The conversion of plasminogen to plasmin was initially
identi¢ed as the key event in ¢brinolysis, a process that main-
tains vascular patency [1]. Since then, the plasminogen-plas-
min system has also been implicated in other (patho)physio-
logical functions, like cancer, restenosis, embryonic
development, ovulation and certain brain processes [2]. The
system is activated via the serine proteinases urokinase-type
plasminogen activator (u-PA) and tissue-type plasminogen ac-
tivator (t-PA), which is the main activator during ¢brinolysis
[1]. Studies with t-PA de¢cient mice underscored its involve-
ment in brain processes like long term potentiation and ex-
citotoxin induced neuronal cell death in the hippocampus
[3,4].
The human t-PA gene promoter contains two major tran-
scription start sites, which are dependent on a TATAA box
and an initiator element, respectively [5,6]. Transcription of
the human t-PA gene is regulated through a cAMP responsive
like element (CRE like), which mediates induction by protein
kinase C (PKC) [6]. An in vivo footprinting analysis of the
human t-PA promoter in HeLa cervix carcinoma cells and in
human umbilical vein endothelial cells revealed the presence
of two Sp1 binding sites (Sp1c : bp 372 to 366; Sp1d : bp
348 to 339), just upstream from the initiator element, a sit-
uation which is often associated with TATAA less promoters
[7]. Sp1 binding to these sites is assumed to attract the RNA
polymerase II pre-initiation complex through a tethering fac-
tor or through speci¢c interactions with the TATAA box
binding protein (TBP) or TBP associated factors [8,9]. The
Sp1-related transcription factor Sp3 also interacts with GC
or GT boxes and depending on the promoter context, can
either repress or activate transcription, or even cooperate
with Sp1 [10].
The hormonal regulation of the human t-PA gene transcrip-
tion is mediated through an enhancer located at 37.2 kb from
the initiator element. This enhancer confers a response to all
steroid hormones, except estrogens, and to retinoic acid (RA)
[11,12]. The steroid hormone response is mediated through a
hormone responsive unit consisting of four glucocorticoid re-
sponsive elements (GRE) located at bp 37960, 37942, 37703
and 37501. In contrast, only one retinoic acid responsive
element, which comprises a DR5 element located at bp
37319, mediates the induction of the human t-PA gene by
RA.
An important issue concerning enhancer action is enhancer/
promoter selectivity which allows enhancers to discriminate
between di¡erent promoters [13]. In order to confer the hor-
monal stimulus, the far upstream t-PA enhancer must be able
to induce the t-PA promoter activity in a speci¢c way. This
might be achieved through interactions between transcription
factors bound to the t-PA enhancer and to the t-PA promoter.
In the present study, we have investigated whether the induc-
tion by RA and dexamethasone (DEX), a synthetic analogue
of glucocorticoids, both mediated through the enhancer, re-
quired the Sp1 binding sites previously characterized in the
human t-PA promoter.
It is shown that Sp1 and Sp3 bind to the t-PA promoter
and induce promoter activity in SL2 Drosophila cells, devoid
of endogenous Sp1 and Sp3. Transient transfection studies in
these SL2 cells and in HT1080 ¢brosarcoma cells showed that
the RA but not the DEX induction was dependent on the two
Sp1 sites present in the human t-PA promoter.
2. Materials and methods
2.1. Reagents
Human HT1080 ¢brosarcoma and SL2 Drosophila cells were ob-
tained from the American Type Culture Collection (Rockville, MD,
USA) and from Dr. W. Wahli (Institut de Biologie Animale, Univer-
site¤ de Lausanne, Switzerland) respectively. t-PA520CREmut-CAT
was a gift from Dr. R. Medcalf (Department of Medicine, Box Hill
Hospital, Victoria, Australia). The polyclonal antibody against Sp3,
the insect cell expression vectors for Sp1 (pPacSp1), Sp3 (pPacSp3),
and GR (pPacGR), the reporter constructs (GRE)6Adh-CAT and
pPadhLGal and the bacterial expression vector for the Sp1 DNA bind-
ing domain (pET3b/Sp1BamHI) were obtained from Dr. G. Su«ske
(Institut fu«r Molekularbiologie und Tumorforschung, Philips Univer-
sita«t Marburg, Marburg, Germany). Insect cell expression vectors for
RAR (pPacRAR) and RXR (pPacRXR) were a gift from Dr. N. Gill
(Division of Endocrinology and Metabolism, University of California,
San Diego, CA, USA).
Dulbecco’s modi¢ed Eagle’s medium (DMEM) and all medium
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supplements were purchased from Life Technologies, Inc. (Gent, Bel-
gium), tissue culture recipients from Corning, Inc. (New York, USA)
and Becton Dickinson (Franklin Lakes, NJ, USA), retinoic acid (RA),
dexamethasone (DEX) and chloramphenicol from Sigma (St. Louis,
MO, USA). DNA puri¢cation columns from Qiagen (Chatsworth,
CA, USA), acetyl-CoA and [3H]acetyl-CoA from ICN Biomedicals
(Costa Mesa, CA, USA), Lipoluma from Lumac-LSC (Olen, Bel-
gium), luciferin substrate, the full length Sp1 protein and the Erase
a Base system from Promega (Madison, WI, USA). Bradford reagent
was purchased from BioRad (Hercules, CA, USA), Galacto Light
system from Tropix, Inc. (Bedford, MA, USA), oligonucleotides
and poly(dIdC)Wpoly(dIdC) from Amersham Pharmacia Biotech
(Gent, Belgium). Polyclonal antibodies directed against the Sp1 pro-
tein was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA, USA).
2.2. Reporter constructs
Isolation of t-PA upstream sequences and their incorporation in
chloramphenicol acetyltransferase (CAT) reporter plasmids has been
described previously [11]. All genomic sequences analyzed in this
study are numbered relative to the transcription start site of Hender-
son and Sleigh, 1992 [5]. All reporter constructs have a modi¢ed
pBLCAT3 backbone obtained by deletion of the cryptic AP1 site,
present in the latter backbone, by a HindIII-AatII digest, resulting
in pBLCAT3/vAP1. For the t-PA632-CAT/vAP1 construct, fusion
to the CAT gene was done at bp +197 of the t-PA gene and the 5P
endpoint coordinate is 3632. Introduction of mutations in reporter
constructs was based on the polymerase chain reaction (PCR). The
mutations in the Sp1c and/or Sp1d sites in t-PA632-CAT/vAP1 were
introduced with the Sp1c/dmut, Sp1cmut or Sp1dmut primers. Sequen-
ces of the oligonucleotides used in the mutagenesis are listed in Table
1. The 5P progressive deletion mutants of the t-PA promoter were
obtained by 5P exonuclease III digestion of t-PA632-CAT/vAP1
(Erase a Base system). In these constructs the human t-PA promoter
is fused at bp +197 to the CAT gene, and the 5P deletion endpoints are
as indicated: t-PA490-CAT/vAP1, t-PA242-CAT/vAP1, t-PA205-
CAT/vAP1, t-PA163-CAT/vAP1, t-PA110-CAT/vAP1, t-PA39-CAT/
vAP1. The t-PA enhancer (t-PA2.4 ; bp 39578 to 37144) was cloned
as a HindIII fragment in front of t-PA632-CAT/vAP1, t-PA632Sp1c/
dmut-CAT/vAP1 and t-PA520CREmut-CAT/vAP1.
All mutations were con¢rmed by cycle sequencing with the ABI
Prism 310 Genetic Analyzer (Perkin Elmer, Zaventem, Belgium). Gen-
erated sequences were analyzed with the GCG software at the Belgian
EMBNET Node (BEN).
2.3. Cell culture and transfection
HT1080 cells were maintained in supplemented DMEM, containing
glutamine (1 mM), penicillin (100 IU/ml), streptomycin (100 Wg/ml),
and 10% heat inactivated fetal calf serum. For transfection, cells were
seeded at a density of 2^4U104 cells/cm2 and grown overnight at 37‡C
in a humidi¢ed 95% air, 5% CO2 atmosphere in medium with 5% heat
inactivated charcoal treated fetal calf serum. The calcium phosphate
co-precipitation method was applied to a 6-well dish using a DNA
mixture of 20^60 Wg of reporter plasmid and where mentioned, with
1 Wg of pRSVluc. Cells were treated with the indicated hormone 12 h
after the glycerol shock. SL2 Drosophila cells were maintained in M3
medium supplemented with nystatin (10 U/ml), glutamine (1 mM),
penicillin (100 IU/ml), streptomycin (100 Wg/ml), and 10% heat inac-
tivated insect cell quali¢ed fetal calf serum at 28‡C. For transfection,
SL2 cells were seeded at a density of 2.5U105 cells/cm2 in M3 medium
supplemented as described above but with 5% heat inactivated insect
cell quali¢ed fetal calf serum. The calcium phosphate co-precipitation
method was used with 16 Wg of reporter construct, 1 Wg of each of the
pPac expression vectors and 1 Wg of pPadhLGal for three wells of a 6-
well plate. This DNA mixture was adjusted to 20 Wg with empty pPac
expression vector. Cells were treated with the indicated hormones 12 h
after transfection. DEX was dissolved in ethanol at a concentration of
1033 M and stored at 380‡C. RA was dissolved in dimethylsulfoxide
at a concentration of 1032 M and stored at 380‡C. The appropriate
concentration was added to the medium in a volume corresponding to
0.1% of the culture medium. Control medium contained an equal
amount of excipient.
After transfection, cell extracts were prepared by three freeze-thaw
cycles in 100 mM Tris-HCl pH 7.8, 5 mM EDTA. CAT activity was
determined by the liquid scintillation method [14]. Luciferase or
L-galactosidase activity, used as an indicator for the transfection e⁄-
ciency, were measured in a Berthold luminometer after addition of the
luciferin or the Galacton substrate respectively. All data shown rep-
resent values obtained from at least two independent experiments,
each performed in triplicate (n = 6 or 9) and for which at least two
di¡erent plasmid preparations were used. All data are depicted as
mean þ S.E.M.
2.4. Electrophoretic mobility shift assay
HT1080 nuclear extract was prepared as described [12]. The Sp1
DBD was expressed into BL21DELysS bacteria from the pET3b/
Sp1BamHI expression vector, and puri¢ed as described [15].
Sequences of the oligonucleotides used in electrophoretic mobility
shift assay are listed in Table 1. Twenty pmol of DNA oligonucleo-
tides were labeled by the T4 polynucleotide kinase in the presence of
[Q32P]-ATP and puri¢ed after electrophoresis on a 20% polyacrylamide
gel. HT1080 cell nuclear extract and Sp1 DBD were incubated for
25 min at room temperature in the binding bu¡er (10 mM Tris pH 8,
1 mM dithiotreitol, 500 WM EDTA, 80 mM KCl, 0.1% Triton X-100,
1Wg BSA, 0.5 Wg poly(dIdC), 12% glycerol) containing 20 000 cpm of
the labeled oligonucleotide. HT1080 nuclear extract was pre-incubated
with polyclonal antibodies directed against Sp1 or Sp3 for 10 min at
room temperature. All competitor oligonucleotides were added simul-
taneously with the labeled oligonucleotide in the indicated molar ex-
cess.
The samples were loaded on a 4% polyacrylamide gel and separated
by electrophoresis at 4‡C for 90 min in 0.5UTris-borate bu¡er. Gels
were dried and the bands were visualized by overnight autoradiogra-
phy at 380‡C.
3. Results
3.1. Interaction of Sp1 and Sp3 with sequences in the human
t-PA promoter
RA and DEX were previously shown to induce t-PA gene
transcription in HT1080 ¢brosarcoma cells [11]. In order to
evaluate a role of the proximal promoter in these responses,
we ¢rst investigated whether nuclear extracts from these cells
contained proteins binding the two Sp1 sites (Sp1c and Sp1d)
previously identi¢ed in the t-PA promoter [7].
As a control, electrophoretic mobility shift assay (EMSA)
was performed with the bacterially expressed Sp1 DNA bind-
ing domain (Sp1DBD) and a radiolabeled oligonucleotide
comprising the Sp1d sequence (Fig. 1A, lanes 2^6). The com-
plex formed was speci¢c since it was competed by an oligo-
nucleotide comprising the Sp1 consensus sequence, but not by
an oligonucleotide comprising the unrelated NF-I sequence
(lanes 3, 4 and 5, 6). Several protein-DNA complexes were
observed when a similar experiment was performed with
HT1080 nuclear extracts (Fig. 1A, lanes 7^13). The presence
of Sp1 and Sp3 in the two slower migrating complexes was
Table 1
Oligonucleotides
Name Sequence
Sp1c ACAGAAACCCGCCCAGCCGGGG
Sp1cmut ACAGAAACACGCACAGCCGGGG
Sp1d CCACCGACCCCACCCCCTGCCTG
Sp1dmut CCACCGACACTAGTCCCTGCCTG
Sp1c/d ACAGAAACCCGCCCAGCCGGGGCCACCGACCC-
CACCCCCTGCCTG
Sp1c/dmut ACAGAAACACGCACAGCCGGGGCCACCGACACTAGT-
CCCTGCCTG
Sp1cons ATTCGATCGGGGCGGGGCGAGC
Sequences of the oligonucleotides used in the electrophoretic mobil-
ity shift assays or to introduce site speci¢c mutations in t-PA632-
CAT/vAP1.
Putative cis-elements are represented in bold in the wild-type se-
quences. Introduced mutations are underlined.
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shown by co-incubation with speci¢c antibodies (Fig. 1A,
lanes 8, 9). Speci¢city of these interactions was shown by
competition as above (Fig. 1A, lanes 10^13). Similar results
were obtained for the radiolabeled Sp1c oligonucleotide (Fig.
1A, lanes 15^26), although the complexes observed were
weaker. Binding of the Sp1DBD protein to the Sp1 consensus
oligonucleotide was challenged by competition with unlabeled
Sp1c or Sp1d oligonucleotides in EMSA (Fig. 1B). Addition
of a 100-fold excess of Sp1c (Fig. 1B, lane 3) was less e⁄cient
than addition of Sp1d (Fig. 1B, lane 6), suggesting a higher
a⁄nity of Sp1 for Sp1d than for Sp1c.
In conclusion, Sp1 and Sp3 present in HT1080 nuclear ex-
tracts interact in vitro with two sequences (Sp1c and Sp1d)
located just upstream from the initiator element in the t-PA
promoter.
3.2. Involvement of Sp1 and Sp3 in human t-PA promoter basal
activity
To assess the importance of Sp1 and Sp3 for basal t-PA
promoter activity, SL2 Drosophila cells which are devoid of
these transcription factors, were transiently transfected with a
reporter construct containing the t-PA promoter (t-PA632-
CAT/vAP1) and expression vectors encoding Sp1 and Sp3.
In the absence of Sp1 or Sp3, no t-PA promoter activity
was detected in SL2 cells. A 16 þ 1.2-fold induction of CAT
activity was observed in the presence of Sp1 compared to its
absence, while co-expression of Sp3 yielded a 5 þ 0.1-fold ac-
tivation (Fig. 2A). Simultaneous expression of Sp1 and Sp3
led to a synergistic activation of t-PA632-CAT/vAP1 (40.5 þ
1.5-fold).
Site speci¢c mutations of Sp1c and Sp1d (Sp1c/dmut) com-
pletely abolished Sp1 binding as shown when EMSA was
performed with a radiolabeled oligonucleotide encompassing
the two sites and puri¢ed Sp1 (Fig. 2B). These mutations were
introduced in the reporter vector (t-PA632Sp1c/dmut-CAT/
vAP1) leading to a 2-fold reduction of the activation by
Sp1, but not a¡ecting response to Sp3 (Fig. 2A). The syner-
gistic induction by Sp1 and Sp3 was strongly a¡ected indicat-
ing that the Sp1c and Sp1d sites were involved. The reporter
vectors carrying either or both Sp1c and Sp1d mutations were
then evaluated in transient transfection of HT1080 cells re-
vealing a 60^70% reduction in basal t-PA promoter activity
(Fig. 2C).
Since mutation of the Sp1c and Sp1d sites did not result in
complete suppression of the Sp1 activation in the SL2 cells,
progressive deletion mutants of the t-PA promoter were used
to search for additional Sp1 responsive elements (Fig. 3). As
expected, Sp1 activation of t-PA-CAT reporter constructs was
strongly a¡ected by deletion of the Sp1c and Sp1d sites
(t-PA39-CAT/vAP1 versus t-PA110-CAT/vAP1). In addition,
a 3- to 4-fold decrease in Sp1 activation was observed upon
deletion of bp 3242 to 3205 (t-PA242-CAT/vAP1 versus
t-PA205-CAT/vAP1), a region encompassing the previously
identi¢ed CRE like element. Several complexes were formed
in EMSA between HT1080 nuclear extract and an oligonu-
cleotide covering this region, however they did not include
Fig. 1. A: Binding of Sp1 and Sp3 to the Sp1c and Sp1d oligonucleotides. EMSA was performed with the indicated 32P-labeled oligonucleoti-
des and with the Sp1 DBD (lanes 2^6, 15^19) or HT1080 nuclear cell extract (lanes 7^13, 20^26) as described in Section 2. The Sp3- and Sp1-
DNA complexes are indicated by arrows. Competition experiments were performed with 500-fold (lanes 4, 6, 11, 13, 17, 19, 24, 26) or 100-fold
(lanes 3, 5, 10, 12, 16, 18, 23, 25) molar excess of unlabeled oligonucleotide. B: Comparison of Sp1 a⁄nity for Sp1c and Sp1d. Binding of
Sp1DBD to the oligonucleotide comprising the Sp1 consensus site was competed with non-labeled oligonucleotides comprising the Sp1c, the
Sp1d, the Sp1 cons (consensus) and the unrelated NF-I sequence. A 500-fold (lanes 2, 5, 8, 11), 100-fold (lanes 3, 6, 9, 12) or 10-fold (lanes 4,
7, 10, 13) molar excess of competitor was used. DNA-protein complexes are shown.
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Sp1, nor could puri¢ed Sp1 bind to this sequence (data not
shown). Further studies are required to elucidate this phenom-
enon.
In conclusion, these data demonstrate that Sp1 and Sp3
activate t-PA promoter activity in SL2 insect cells both indi-
vidually and synergistically. Mutations of the Sp1c and Sp1d
sites reduce the activation by Sp1 in SL2 cells and the basal
promoter activity in HT1080 cells.
3.3. Involvement of Sp1c and Sp1d in the hormonal response of
the t-PA enhancer
We then evaluated whether the Sp1c and Sp1d sites in the t-
PA promoter played a role in the hormonal inductions medi-
Fig. 2. Activation of the human t-PA promoter by Sp1 and Sp3. A:
Right panel: schematic representation of the t-PA reporter con-
structs. The Sp1c/d sites and mutations are indicated with a bold
bar and crosses respectively. Left panel: SL2 cells were co-trans-
fected with 4 Wg of either t-PA632-CAT/vAP1 (wt) or t-PA632Sp1c/
dmut-CAT/vAP1 (Sp1c/dmut) reporter vector, and with 250 ng of
expression vector either without insert (3) or with the Sp1 or Sp3
cDNA as indicated. For the synergy study, 125 ng of Sp1 and Sp3
expression vector were added simultaneously (Sp1/Sp3). In all cases,
250 ng of pPadhLgal were added, allowing correction for transfec-
tion e⁄ciency. Cells were harvested after 24 h and CAT and L-gal-
actosidase activities were determined. The fold induction of CAT
activity in the presence of Sp1 and/or Sp3 compared to the CAT ac-
tivity in their absence is represented. B: Evaluation of the Sp1c/
dmut sequence for Sp1 binding. EMSA was performed with 32P-la-
beled Sp1c/s itsd and Sp1c/dmut oligonucleotides and the full
length puri¢ed Sp1 protein (Promega) as described in Section 2.
Competition was performed with 500-fold molar excess of competi-
tor (Sp1 consensus or NF-I oligonucleotides). C: Involvement of
the Sp1c and Sp1d sites in t-PA promoter activity in human cells.
HT1080 cells were transiently transfected with the t-PA632-CAT/
vAP1 reporter vector either wild-type (wt) or carrying mutations in
the Sp1c or Sp1d site, or both sites as indicated. In all cases,
pRSVluc. was added, allowing correction for transfection e⁄ciency.
Cells were harvested after 36 h and CAT and luciferase activities
were determined. Data correspond to CAT activities relative to the
wild-type construct. Details are provided in Section 2.
Fig. 3. Delineation of the regions involved in the Sp1 activation of
the t-PA promoter. Left panels: Schematic representation of the re-
porter constructs, with the cis-elements Sp1c, Sp1d and CRE indi-
cated. SL2 cells were transfected with 4 Wg of the indicated reporter
constructs, 250 ng of Sp1 expression vector and 250 ng of pPadhL
gal. After 24 h cells were harvested and CAT and L-galactosidase
activities were determined. Fold induction of the CAT activity in
the presence versus absence of Sp1 is represented. Correction for
transfection e⁄ciency was performed via the L-galactosidase activ-
ity.
Fig. 4. Role of Sp1 binding sites in the t-PA promoter for hormonal
induction mediated by the t-PA enhancer. Left panels: Schematic
representation of the reporter constructs, with the cis-elements Sp1c,
Sp1d, DR5 the glucocorticoid responsive unit (GRU) and mutations
are indicated by vertical lines, an oval, squares and crosses. SL2
cells were transfected with 4 Wg of either t-PA2.4-632-CAT/vAP1 or
t-PA2.4-632Sp1c/dmut-CAT/vAP1 (panel A), and either (GRE)6-
Adh-CAT or t-PA2.4-632-CAT/vAP1 (panel B). Co-transfection was
performed with 250 ng of pPadhLgal and 250 ng of the indicated
expression vectors. The total amount of expression vector was ad-
justed to 750 ng with empty expression vector for each experiment.
The following day the cells were stimulated for 24 h with 1037 M
RA (panel A) or with 1037 M DEX (panel B). Cells were harvested
and CAT and L-galactosidase activities were determined. The data
represent the fold induction in the presence versus absence of the in-
dicated expression vectors. Correction for transfection e⁄ciency was
performed with L-galactosidase activity values.
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ated by the t-PA enhancer. A reporter construct containing
the t-PA enhancer linked to the t-PA promoter (t-PA2.4-632-
CAT/vAP1) was evaluated in SL2 cells : as expected, co-trans-
fection with an expression vector encoding Sp1, led to a
32.5 þ 2.7 basal activation (Fig. 4A). Co-expression of retinoid
receptors RAR and RXR and addition of 1037 M RA did not
a¡ect t-PA2.4-632-CAT/vAP1 activity. However, further ad-
dition of an Sp1 expression vector allowed induction of the
CAT activity 111.9 þ 9.3-fold, showing that the induction by
RA was completely dependent on the presence of Sp1. Muta-
tion of the Sp1c/d sites in the t-PA promoter reduced the basal
activation by Sp1, as already shown (Fig. 2A), but also com-
pletely eliminated induction by RA (Fig. 4A), underscoring
the role of Sp1c and Sp1d. In contrast, co-expression of
Sp3, RAR and RXR only showed a 5.8 þ 0.1-fold induction
after RA treatment compared to a 4.5 þ 0.15-fold induction
for co-expression of Sp3 alone, indicating that binding of Sp3
to the human t-PA promoter is not su⁄cient for the RA
induction mediated by the t-PA enhancer.
A similar analysis was performed to evaluate a role of Sp1
in response to glucocorticoids (DEX). No induction by 1037
M DEX, but a repression of the activation by Sp1 was ob-
served for t-PA2.4-632-CAT/vAP1 upon co-expression of Sp1
and the glucocorticoid receptor (GR) (Fig. 4B). The positive
control (GRE)6-Adh-CAT, which contains six glucocorticoid
response elements in front of the insect Adh promoter, was
strongly induced in the same conditions, indicating the func-
tionality of the GR expression vector.
The impact of the Sp1c/d mutations on the RA responsive-
ness of the t-PA reporter construct was then evaluated in
human HT1080 cells. Transient transfection of the HT1080
cells with t-PA2.4-632-CAT/vAP1 led to a 2 þ 0.09-fold induc-
tion upon treatment with 1036 M RA (Fig. 5A, a). In con-
trast, no e¡ect of RA could be observed on transient expres-
sion of t-PA632Sp1c/dmut-CAT/vAP1 (Fig. 5A, b). The Sp1
requirement for the induction by RA was speci¢c since muta-
tion of the cyclic AMP response element (CRE) in the t-PA
promoter (t-PA2.4-520CREmut-CAT/vAP1) did not a¡ect the
RA response (2.5 þ 0.04-fold). In contrast, the Sp1c/d muta-
tions did not a¡ect the induction by DEX of t-PA2.4-632-
CAT/vAP1 (Fig. 5B).
In conclusion, transient transfection analysis in SL2 and
HT1080 cells showed that the Sp1c and Sp1d sites are re-
quired for the induction by RA, but not by DEX, although
both responses are mediated through the t-PA enhancer. In
contrast, a functional t-PA CRE is not required for the RA
induction in HT1080 cells.
4. Discussion
In the present study we ¢rst showed that binding of Sp1
and/or Sp3 to the Sp1c and Sp1d sites in the proximal t-PA
promoter was required for basal activity in Drosophila SL2
cells. EMSA competition experiments with the Sp1 consensus
element and the two t-PA Sp1 sites revealed that the most
upstream sequence (Sp1c) has an approximately 10-fold lower
a⁄nity for Sp1 than the downstream site (Sp1d). Mutation of
either site severely hampered the basal activity of the t-PA
promoter in HT1080 cells, indicating that both sites were as
important. Some basal activity in HT1080 cells, as well as
some activation by Sp1 in SL2 cells, were still observed with
the t-PA promoter carrying the double mutation, suggesting
that additional cis-elements were involved. Indeed, evaluation
of progressive deletion mutants of the t-PA promoter in the
SL2 cells, delineated a second region important for activation
by Sp1 which coincides with the CRE element. However, no
direct interaction with Sp1 was observed, suggesting an alter-
native mechanism for this Sp1 activation.
Simultaneous expression of Sp1 and Sp3 in SL2 cells stimu-
lated t-PA promoter activity in a synergistic way compared to
Sp1 or Sp3 alone. In analogy to the t-PA promoter, Sp3 also
activates the leukocyte integrin gene CD11c through two
binding sites [16], indicating that Sp3 does not always act as
a repressor. Intriguingly, if the mutations disrupting the Sp1c
and Sp1d sites strongly a¡ected the activation by Sp1, they
only had a slight e¡ect on the activation by Sp3 suggesting
that Sp3 could induce the t-PA promoter through alternative
cis-elements.
Previous studies have shown that the enhancer, which is
located at 37.2 kb upstream from the human t-PA gene,
mediates induction by RA and DEX [11,12]. The present
study revealed a unique role for the Sp1c and Sp1d sites of
the proximal promoter in the hormonal response mediated by
this enhancer. The induction of the t-PA gene by RA could
only be reconstituted in SL2 cells upon co-expression of Sp1,
but not of Sp3, in addition to RAR/RXR and t-PA2.4-632-
CAT/vAP1. Mutation of the Sp1c and Sp1d sites in this re-
porter construct completely suppressed induction by RA. In
contrast, the induction by DEX could not be reproduced
upon co-transfection of the SL2 cells with t-PA2.4-632-CAT/
vAP1 and expression vectors for Sp1 and GR, suggesting that
additional factors were required for this hormonal response.
The role of Sp1 in the induction by RA was con¢rmed in
Fig. 5. Role of Sp1 elements present in the t-PA promoter for in-
duction by RA and DEX mediated by the t-PA enhancer in human
cells. Left panels: Schematic representation of the reporter con-
structs. Right panels: HT1080 cells were transfected with reporter
vectors t-PA2.4-632-CAT/vAP1 (a), t-PA2.4-632Sp1c/dmut-CAT/
vAP1 (b) and t-PA2.4-520-CAT/vAP1 (c). Cells were grown for 24 h
with either control medium, 1037 M RA (panel A) or 1037 M DEX
(panel B). Cells were harvested and CAT activity was determined.
Results are represented as fold induction of the CAT activity in
hormone treated versus control cells.
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mammalian cells. Indeed, no RA induction was observed
upon transient transfection of HT1080 cells with t-PA2.4-
632Sp1c/dmut-CAT/vAP1 treated with 1036 M RA. To inves-
tigate whether the loss of induction by RA was not a conse-
quence of the lower basal activity of the t-PA promoter mu-
tated in the Sp1 sites, another mutation known to decrease the
basal level was evaluated in HT1080 cells : mutation of the
CRE did not a¡ect the induction by RA, indicating a speci¢c
Sp1 requirement. RA receptors have been shown to regulate
gene transcription by interaction with other transcription fac-
tors, such as AP2 [17]. The speci¢c Sp1 requirement for the
induction by RA, but not by DEX, might indicate a direct or
indirect interaction between RAR/RXR and Sp1. Direct pro-
tein-protein interactions between Sp1 and a number of nuclear
receptors, like COUP-TF and ER, have been reported [18,19].
Moreover, a multi-protein complex comprising Sp1, CBP and
the progesterone receptor regulates transcription of the
p21WAF1 cyclin dependent kinase inhibitor gene in breast can-
cer cells [20], while Sp1, PPAR and RXR synergistically in-
duce the transcription of the acyl co-enzyme A oxidase pro-
moter [21]. Alternatively, an indirect interaction might be
mediated by the multi-subunit cofactor required for Sp1 acti-
vation (CRSP) that was recently identi¢ed and contains the
nuclear hormone receptor co-activator TRIP2/PBP previously
shown to interact with RXR among others [22]. Whether a
direct or indirect protein-protein interaction between Sp1 and
RAR/RXR is responsible for the observed induction by RA
of the human t-PA gene remains to be investigated. Intrigu-
ingly, Sp3 driven t-PA promoter activity could not support
the RA induction, identifying new divergent functions be-
tween the Sp1 and Sp3 proteins. Indeed, a transcriptional
inhibitory domain has been identi¢ed in Sp3 and is lacking
in Sp1. Further studies should evaluate whether this domain
prevents support of RA induction of the t-PA gene, and
whether this phenomenon has a physiological relevance for
t-PA expression in tissues with di¡erent ratios of the two
factors.
The need for Sp1 binding to the t-PA promoter for induc-
tion by RA mediated through the DR5 element in the t-PA
enhancer could also re£ect some kind of promoter/enhancer
selectivity [13,23]. Recently it was shown that the AE1 en-
hancer from the Drosophila Antennapedia gene complex pref-
erentially activates a TATAA box containing promoter [24]. A
similar situation could be envisioned for the t-PA gene: the
RAR/RXR heterodimer bound to the t-PA enhancer might be
targeted only to the t-PA promoter because of its need for the
Sp1 sites.
In conclusion, Sp1 and Sp3 were shown to activate the t-PA
promoter, by interacting with the two Sp1 sites upstream from
the initiator element. Binding of Sp1, but not of Sp3, to these
elements was a prerequisite for induction by RA, but not by
DEX, mediated by the t-PA enhancer.
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